EMERYVILLE, Calif.,
Jan. 6, 2021 /PRNewswire/
-- Dynavax Technologies Corporation (Nasdaq: DVAX), a
biopharmaceutical company focused on developing and commercializing
vaccines, today announced that Ryan
Spencer, Chief Executive Officer, will present at the H.C.
Wainwright Virtual BioConnect 2021 Conference being held
January 11-14, 2021.
The on demand presentation will be available, beginning
Monday, January 11, 2021 at
6:00 a.m. E.T. and may be accessed
through the "Events & Presentations" page on the "Investors"
section of the Company's website at
http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial stage
biopharmaceutical company developing and commercializing novel
vaccines. The Company's first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the
U.S. for prevention of infection caused by all known subtypes of
hepatitis B virus in adults age 18 years and older. Dynavax is also
advancing CpG 1018 as a premier vaccine adjuvant through research
collaborations and partnerships. Current collaborations are focused
on adjuvanted vaccines for COVID-19, pertussis and universal
influenza. For more information, visit www.dynavax.com and
follow the company on LinkedIn.
Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-bioconnect-2021-conference-301202218.html
SOURCE Dynavax Technologies